Tag Archive for: Clinical Trial

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

/in

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study Boston, Massachusetts and Lausanne, Switzerland, 10 June 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces the submission of a […]

Read more

Bionical Emas and Pharma Resources Announce Exclusive Global Clinical Trial Supply Partnership

/in

Strategic agreement secures access to essential oncology injectables for clinical trials as European shortages intensify LONDON, UK – 29 May 2025: Bionical Emas, a global provider of Clinical Trial Services, announces an exclusive global clinical trial supply agreement with Pharma Resources GmbH, German pharmaceutical company and marketing authorization holder, specialized in oncology. This strategic partnership […]

Read more

Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia

/in

Phase Ib/IIa trial is to evaluate the efficacy of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia A total of six participants have been enrolled in the trial across two sites – one in the Netherlands and one in the United Kingdom Copenhagen, Denmark, 09 May 2025 – Vesper Bio ApS (“Vesper” […]

Read more

Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025

/in

Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated Cohort 8 expected to start soon Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started Amendment of contract with HealthCare Royalty; payment of USD 20 million significantly extends cash reach Ladenburg, Germany, 24 […]

Read more

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

/in

Enrolment completed – 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026 Capability to obtain market approval is further strengthened with the appointment of Rob Eyers as Chief Technology Officer. EINDHOVEN, The Netherlands, 7 January 2025 – Xeltis, a leading […]

Read more